Genentech Alecensa OKd as First Adjuvant Treatment for ALK-Positive Early-Stage Lung Cancer

 Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC) –

– This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy –

– The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection –

https://www.businesswire.com/news/home/20240418088206/en/FDA-Approves-Genentechs-Alecensa-as-First-Adjuvant-Treatment-for-People-With-ALK-Positive-Early-Stage-Lung-Cancer